Artwork

Conteúdo fornecido por Hercules Capital. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Hercules Capital ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

#24 – Scaling up in Biotech, Raising $300M for a Single Pharma Product | Mark Hahn

31:57
 
Compartilhar
 

Manage episode 379553432 series 2940551
Conteúdo fornecido por Hercules Capital. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Hercules Capital ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Successful biotech companies require a capable CFO to guide the company through conducting clinical trials, securing regulatory approvals, establishing scalable production, and adeptly conveying value to healthcare stakeholders.
Mark Hahn is a seasoned executive with over 25 years of CFO experience. He is currently the CFO of Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
In this episode, Hercules Capital’s Janice Bourque is joined by Hahn to discuss his experience as CFO of Verona, Dova, and Cempra, the intricacies of single-asset companies, preparing a company for FDA approval and commercialization, identifying a successful launch, and much more.
Topics Include:

  • Mark’s experience as CFO of Verona, Dova, and Cempra
  • The intricacies of single-asset companies and the challenges when raising capital
  • The steps a CFO should take when preparing for FDA approval and commercialization
  • What biotech companies should focus on before presenting to the FDA
  • How to know when you’ve had a successful launch
  • Mark’s experience as a CFO with a late-stage asset
  • And other topics…

Mark Hahn is a seasoned CFO with over 25 years of experience. He joined Verona Pharma as CFO in 2020. Prior to Verona, Hahn served as CFO of Dova Pharmaceuticals through its 2019 acquisition by Swedish Orphan Biovitrum for $915 million. There, he was instrumental in raising capital and launching the company’s first commercial product. Prior to Dova, Hahn was CFO of Cempra, where he led the company’s IPO and several subsequent follow-on offerings until the company’s acquisition by Melinta Therapeutics in 2017. Earlier, Hahn was the CFO of several other public and private companies. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.

  continue reading

32 episódios

Artwork
iconCompartilhar
 
Manage episode 379553432 series 2940551
Conteúdo fornecido por Hercules Capital. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Hercules Capital ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

Successful biotech companies require a capable CFO to guide the company through conducting clinical trials, securing regulatory approvals, establishing scalable production, and adeptly conveying value to healthcare stakeholders.
Mark Hahn is a seasoned executive with over 25 years of CFO experience. He is currently the CFO of Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
In this episode, Hercules Capital’s Janice Bourque is joined by Hahn to discuss his experience as CFO of Verona, Dova, and Cempra, the intricacies of single-asset companies, preparing a company for FDA approval and commercialization, identifying a successful launch, and much more.
Topics Include:

  • Mark’s experience as CFO of Verona, Dova, and Cempra
  • The intricacies of single-asset companies and the challenges when raising capital
  • The steps a CFO should take when preparing for FDA approval and commercialization
  • What biotech companies should focus on before presenting to the FDA
  • How to know when you’ve had a successful launch
  • Mark’s experience as a CFO with a late-stage asset
  • And other topics…

Mark Hahn is a seasoned CFO with over 25 years of experience. He joined Verona Pharma as CFO in 2020. Prior to Verona, Hahn served as CFO of Dova Pharmaceuticals through its 2019 acquisition by Swedish Orphan Biovitrum for $915 million. There, he was instrumental in raising capital and launching the company’s first commercial product. Prior to Dova, Hahn was CFO of Cempra, where he led the company’s IPO and several subsequent follow-on offerings until the company’s acquisition by Melinta Therapeutics in 2017. Earlier, Hahn was the CFO of several other public and private companies. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.

  continue reading

32 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências